0001834376-25-000062
SEC filingRevenue grew 11.8% YoY to $853.7M, but net loss widened to $35.3M due to higher costs and impairment charges.
InnovAge is the largest healthcare delivery platform by participants focused exclusively on providing all-inclusive, capitated care to high-cost, dual-eligible seniors through the Program of All-Inclusive Care for the Elderly (PACE). The company directly contracts with Medicare and Medicaid on a per member, per month basis, assuming 100% risk for participant healthcare costs. As of June 30, 2025, InnovAge served approximately 7,740 participants across 20 centers in six states: California, Colorado, Florida, New Mexico, Pennsylvania, and Virginia. The typical participant has ten chronic conditions and requires assistance with two or more activities of daily living. Approximately 93% of participants live in their homes or communities.
InnovAge manages its business as one reportable segment: PACE. No revenue share by segment is disclosed.
The core offering is the PACE program, delivered through the InnovAge Platform. Key components include Interdisciplinary Care Teams (IDTs) comprising at least 11 disciplines, community-based care centers, in-home care capabilities, and virtual care. The platform addresses social determinants of health such as economic stability, transportation, and food/nutrition.
InnovAge contracts directly with government payors (Medicare, Medicaid, VA, private pay) without intermediaries. No single customer concentration is disclosed; revenue is derived from capitation payments.
The healthcare industry is highly competitive. InnovAge competes with national, regional, and local providers, as well as payors and alternative managed care programs. Many competitors have longer operating histories or greater resources. Principal competitive factors include participant experience, quality of care, health outcomes, total cost of care, and brand trust.
InnovAge’s growth strategy includes: (1) increasing participant enrollment and capacity within existing centers; (2) building de novo centers in target markets, with recent expansions in Florida; (3) executing tuck-in acquisitions and strategic partnerships, including joint ventures with health systems (e.g., Orlando Health, Tampa General Hospital); and (4) reinvesting in the InnovAge Platform through technology improvements, data analytics, and payor sophistication to drive clinical value and reduce medical costs.
As of June 30, 2025, InnovAge had approximately 2,440 employees, including over 1,600 clinical professionals. The voluntary retention rate was 69% in fiscal year 2025, and 82% of employees reported being proud to work at the company. The workforce is 76% women and 58% minorities. Less than 1% of employees are unionized. The company provides soft skills training, leadership development, and clinical training programs informed by employee surveys.
For fiscal year 2025, InnovAge reported total revenues of $853.7 million, an 11.8% increase from $763.9 million in fiscal 2024. Capitation revenue, which comprises nearly all revenue, rose 11.8% to $852.4 million, driven by a 10.3% expansion in member months (to 89,130) and a 1.4% increase in capitation rates. The member month growth was primarily from California and Colorado centers, plus de novo centers in Florida and the Crenshaw acquisition. Rate increases included a 7.2% Medicaid rate hike partially offset by revenue reserves, and a 2.1% Medicare rate increase partially offset by a prior-year out-of-cycle risk score true-up.
Total operating expenses increased 10.5% to $883.5 million. External provider costs rose 7.0% to $431.2 million, as a 10.3% increase in member months was partially offset by a 3.0% decrease in cost per participant due to lower utilization and in-house pharmacy services. Cost of care (excluding D&A) jumped 17.5% to $268.9 million, driven by a $23.8 million rise in salaries, wages and benefits from increased headcount and wage rates, along with higher consulting, pharmacy, and occupancy costs. Sales and marketing expenses grew 13.1% to $28.2 million, and corporate G&A expenses rose 9.6% to $122.1 million, partly due to $10.1 million accrued for a securities class action settlement. Depreciation and amortization was flat at $19.5 million. The company recorded $13.6 million in impairments and losses on assets held for sale, primarily from halting a de novo center in Louisville. Consequently, operating loss deepened to $29.8 million from $23.2 million. Net loss attributable to InnovAge was $30.3 million versus $21.3 million in the prior year.
InnovAge operates as a single reportable segment: PACE. Within the PACE segment, revenues were $852.7 million, representing nearly all total revenue. The segment's center-level contribution margin (a non-GAAP measure) was $153.2 million, up from $131.7 million, yielding a margin of 18.0% of revenue compared to 17.3% in fiscal 2024. The improvement was driven by revenue growth outpacing center-level expense growth (11.8% vs. 10.8%). The All Other segment (senior housing) contributed minimal revenue of $1.0 million and is being divested, with assets held for sale as of June 30, 2025.
Management expects continued pressure from increased cost of care due to salaries, wages, and third-party provider costs, but believes clinical and operational value initiatives may offset some increases. The company faces headwinds from labor shortages, potential Medicaid funding cuts under the OBBBA (adopted July 2025), and tariff-related supply chain costs. Growth initiatives include expanding de novo centers (though California centers are precluded until remediation), tuck-in acquisitions (e.g., TRHC pharmacy assets acquired in January 2025), and joint ventures (e.g., with Tampa General Hospital in August 2025). No quantitative guidance was provided.
As of June 30, 2025, InnovAge held $64.1M in cash and equivalents and $41.8M in short-term investments, totaling $105.9M in liquid assets. Total debt stood at $60.0M, primarily from the Term Loan Facility, with current maturities of $2.25M. Shareholders' equity was $237.9M, down from $277.6M in the prior year due to net losses and share buybacks. The company's net debt position (cash minus debt) is manageable at $45.9M positive. No inventory or deferred revenue is recognized given the service-based PACE model.
Total lease commitments, including operating and finance leases, amount to $65.0M as of June 30, 2025. Of this, $13.2M is due within one year, $23.5M in years 2-3, and $28.3M thereafter. Additionally, the company has a $100.0M revolving credit facility with $94.8M available (net of $5.2M in letters of credit). No material purchase commitments beyond leases were disclosed. The company accrued $10.1M for a securities class action settlement, though final court approval is pending.
During FY2025, InnovAge repurchased 1.43M shares for $7.3M, exhausting the $7.5M authorization (including a $2.5M increase in September 2024). No dividends were paid. Capital expenditures were $6.3M (0.7% of revenue), primarily for center build-outs. Debt repayments totaled $3.8M, reducing total debt from $66.0M to $60.0M. Subsequent to year-end, the company refinanced its term loan with a $50.7M facility maturing in 2028, improving debt maturity profile.
InnovAge operates as a single reportable segment: PACE. Within PACE, the company has two operating divisions (East and West) aggregated due to similar characteristics. In FY2025, PACE generated $852.7M in revenue (11.8% YoY growth) and a center-level contribution margin of $153.2M. The 'All other' segment (Senior Housing) contributed immaterial revenue of $1.0M. Medicaid accounted for 55% of capitation revenue, Medicare 45%, and private pay less than 1%. The company serves ~7,740 participants across 20 centers in six states.
InnovAge's business is almost entirely dependent on the PACE program (99.8% of revenue), making it highly sensitive to changes in Medicare and Medicaid reimbursement rates, regulations, and funding. The One Big Beautiful Bill Act (OBBBA) and potential Trump administration cuts pose direct threats through reduced federal spending, stricter eligibility requirements, and cost-sharing that could deter enrollment. Ongoing audits by CMS and DOJ, including civil investigative demands under the False Claims Act, create material legal and financial exposure. Past enrollment suspensions in California and Colorado highlight the real risk of sanctions.
The company operates under capitation contracts, assuming full risk for participant care costs. Rising healthcare costs, labor shortages, and inflation have increased expenses without corresponding revenue adjustments. Geographic concentration in Colorado (43% of revenue) amplifies vulnerability to state-specific budget pressures or regulatory changes. The accuracy of risk adjustment data is critical; CMS's expanded RADV audits increase the likelihood of payment recoupments.
Growth depends on recruiting participants, opening de novo centers, and completing acquisitions. Competition from Medicare Advantage and other PACE programs is intensifying. The company's limited geographic footprint (6 states) and recent pharmacy acquisition (no prior experience) add execution risk. Principal shareholders (83% voting power) can control strategic decisions, potentially prioritizing their interests over minority shareholders.
Cybersecurity incidents have occurred in the past, and reliance on third-party vendors handling PHI/PII creates compliance risks under HIPAA and state laws. The company's cybersecurity program is based on NIST CSF but faces evolving threats from AI-enabled attacks.
Overall, the risk factors paint a picture of a company with significant regulatory and operational concentration, ongoing government scrutiny, and limited financial flexibility.
The provided document excerpt does not include the Consolidated Statements of Cash Flows. The text ends before page 73, which contains the cash flow statement. As a result, no cash flow figures (operating, investing, financing, capex, free cash flow, or capital returns) are available for analysis. The balance sheet and income statement are present, but without the cash flow statement, it is impossible to assess cash generation, working capital changes, or capital allocation. Further information is required to complete the analysis.